Navigation Links
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
Date:2/17/2009

in healthy young adults and adults 65 years of age and older are scheduled to begin later this year.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrolment from drug candidates in development by other companies with greater re
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
4. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
5. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
6. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... higher learning, announced today that its RN to BSN and Master of ... awarded full accreditation through June 2020 from the Commission on Collegiate Nursing ...
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning ... at its Denver facility that will usher in a new standard of sticker ... Labels more effectively meet its twin objectives of quality and quantity without ...
(Date:8/4/2015)... Arbor, MI and Topeka, KS (PRWEB) , ... ... ... Information Network (KHIN) announced today their partnership to make the Isabel Symptom Checker ... Isabel Symptom Checker provides consumers a mechanism to check their symptoms in an ...
(Date:8/3/2015)... SC (PRWEB) , ... August 04, 2015 , ... ... published the first-ever Guidelines for Oral-Systemic Thermography.* , The new internationally peer-reviewed Guidelines ... performance of dental and systemic health infrared imaging, in evaluating patients with dental-oral ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3
... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) ... present a company overview at the BMO Capital,Markets ... at 11:00 a.m.,Eastern Time. The conference will be ... City on December 4th and 5th. Mr. Talley ...
... Ind., Nov. 28 Conseco, Inc. (NYSE:,CNO) said today that ... by Long Term Care Group, Inc. (LTCG) for certain,back-office functions ... Run-off segment. Conseco announced earlier this year that it was,considering ... will assume responsibility for the customer call center and the ...
... Special ... and exclusive performances from Cyndi Lauper, Indigo ... YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: SIRI ) today announced ... an exclusive broadcast event on SIRIUS OutQ,109, the nation,s first and only ...
... WASHINGTON, Nov. 28 Today, Lung Cancer,Alliance-Massachusetts ... Cancer. The Report Card gauges the progress being ... Massachusetts. LCA-MA is a chapter of,Lung Cancer Alliance ... cause of cancer deaths nationally, as,well as among ...
... hepatitis liver disease, study finds , , WEDNESDAY, Nov. 28 ... boost the number of clotting cells, called platelets, in ... researchers report. , The new drug is called eltrombopag, ... idiopathic thrombocytopenic purpura (ITP) were able to use the ...
... Risk of developing colorectal cancer is known to ... analysis of 26 studies, involving over 25,000 participants shows ... distinct patterns of genetic inheritance. A team of researchers, ... their findings today in Atlanta at the American Association ...
Cached Medicine News:Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 2Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2Health News:Drug May Help Reverse Clotting Deficiency 2Health News:Drug May Help Reverse Clotting Deficiency 3Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 2Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 3
Designed to safely and easily removing a cataract nucleus, round serrated handle, dull finish....
Round handle dull finish. For right handed surgeon....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: